This page uses content from Wikipedia and is licensed under CC BY-SA.
TOPIX Large 70 Component
TOPIX 100 Component
Nikkei 225 Component
|Founded||(December 6, 1941)|
|Headquarters||4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan|
(President and CEO)
|Revenue||JPY 600.4 billion) (FY 2013)|
US$ 320 million (FY 2013)(JPY 33 billion) (FY 2013)
Number of employees
|10,419 (consolidated, as of March 31, 2014)|
Footnotes / references|
Eisai Co., Ltd. (エーザイ株式会社 Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.
Nihon Eisai Co. Ltd. was established in 1941. In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd. The American subsidiary of the company, Eisai Inc., was established in 1995.
In 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer. Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson.
In September 2006, the company acquired four oncology products from Ligand Pharmaceuticals.
In December 2007, Eisai acquired MGI Pharma, a company specializing in oncology, for $3.9 billion USD. This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer (carmustine) for brain tumors into the Eisai product portfolio.
Eisai Co., Ltd. is based in Tokyo, Japan, while its American subsidiary Eisai Inc. is headquartered in Woodcliff Lake, New Jersey. Eisai maintains medical research headquarters in Woodcliff Lake, New Jersey as well as locations in Japan, the United Kingdom, the Research Triangle in North Carolina, and Massachusetts where the Eisai Research Institute and the Andover Innovative Medicines Institute are based.
The company has manufacturing sites in Japan, North Carolina (USA), Maryland (USA), Bogor (Indonesia), Suzhou (China), Tainan (Taiwan), Visakhapatnam (India) and Hatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.
Some of the key products that Eisai produces or markets with partners include:
Aricept accounted for 40% of Eisai's revenue as of March 2010. The main competitor to Aricept is a generic formulation from Ranbaxy Labs. Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.